Abstract
N/A
Highlights
There is a lack of direct comparative studies for existing field therapies for Actinic keratosis (AK), and our systematic review (SR) and network meta-analysis (NMA) aimed to generate indirect comparative data for the available treatments
Based on the overlap of credible intervals shown in the statistical plots, the novel topical treatment appeared to be as efficacious as existing treatments, and more so than topical placebo or diclofenac 3%
A qualitative assessment of discontinuations due to treatment-related adverse events (TRAEs) showed that in the primary analysis rates were between 1.4% (PDT with 5aminolevulinic acid sensitizer) and 8.2% in all active arms
Summary
Actinic keratosis (AK) is a pre-malignant skin lesion caused by long-term sun exposure. AK may progress to squamous cell carcinoma, so early and effective treatment is essential. There is a lack of direct comparative studies for existing field therapies for AK, and our systematic review (SR) and network meta-analysis (NMA) aimed to generate indirect comparative data for the available treatments. We conducted a SR and NMA to compare the evidence from randomized controlled trials (RCTs) on the efficacy, safety, and discontinuations of key field-directed treatments for AK (5-FU, imiquimod, ingenol mebutate, diclofenac sodium, PDT), plus a novel topical treatment, tirbanibulin
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
